{"product_id":"iressa","title":"IRESSA","description":"\u003cdiv class=\"flex-1 overflow-hidden @container\/thread translate-y-[2rem] -mt-[2rem] pb-[1.5rem]\"\u003e\r\n\u003cdiv class=\"relative h-full\"\u003e\r\n\u003cdiv class=\"flex h-full flex-col overflow-y-auto [scrollbar-gutter:stable]\"\u003e\r\n\u003cdiv class=\"flex flex-col text-sm md:pb-9\"\u003e\r\n\u003carticle class=\"w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]\" dir=\"auto\" data-testid=\"conversation-turn-87\" data-scroll-anchor=\"true\"\u003e\r\n\u003cdiv class=\"m-auto text-base py-[18px] px-6\"\u003e\r\n\u003cdiv class=\"mx-auto flex flex-1 text-base gap-4 md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\"\u003e\r\n\u003cdiv class=\"group\/conversation-turn relative flex w-full min-w-0 flex-col agent-turn @xs\/thread:px-0 @sm\/thread:px-1.5 @md\/thread:px-4\"\u003e\r\n\u003cdiv class=\"flex-col gap-1 md:gap-3\"\u003e\r\n\u003cdiv class=\"flex max-w-full flex-col flex-grow\"\u003e\r\n\u003cdiv class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+\u0026amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"b0c554ce-a28b-4131-a896-ffbb9a42fa15\" data-message-model-slug=\"o3-mini\"\u003e\r\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\"\u003e\r\n\u003cdiv class=\"markdown prose w-full break-words dark:prose-invert light\"\u003e\r\n\u003ch3 data-start=\"432\" data-end=\"456\"\u003eWhat is Gefitinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"457\" data-end=\"849\"\u003e\u003cstrong data-start=\"457\" data-end=\"470\"\u003eGefitinib\u003c\/strong\u003e is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily for the treatment of non‑small cell lung cancer (NSCLC) in patients whose tumors harbor specific EGFR mutations. By blocking EGFR signaling, gefitinib helps to inhibit tumor cell proliferation and induce apoptosis, thereby improving clinical outcomes in appropriately selected patients.\u003c\/p\u003e\r\n\u003cp data-start=\"851\" data-end=\"977\"\u003e\u003cem data-start=\"851\" data-end=\"977\"\u003eReference: U.S. Food and Drug Administration (FDA) Gefitinib Prescribing Information; ClinicalTrials.gov (e.g., NCT00121090)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"979\" data-end=\"982\"\u003e\r\n\u003ch3 data-start=\"984\" data-end=\"1037\"\u003eWhat are the other popular names for Gefitinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"1038\" data-end=\"1164\"\u003eGefitinib is most commonly marketed under the brand name \u003cstrong data-start=\"1095\" data-end=\"1106\"\u003eIressa®\u003c\/strong\u003e. It is also known by its research designation \u003cstrong data-start=\"1153\" data-end=\"1163\"\u003eZD1839\u003c\/strong\u003e.\u003c\/p\u003e\r\n\u003cp data-start=\"1166\" data-end=\"1200\"\u003e\u003cem data-start=\"1166\" data-end=\"1200\"\u003eReference: MedlinePlus; U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1202\" data-end=\"1205\"\u003e\r\n\u003ch3 data-start=\"1207\" data-end=\"1258\"\u003eWhat is the drug classification of Gefitinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"1259\" data-end=\"1459\"\u003eGefitinib is classified as an \u003cstrong data-start=\"1289\" data-end=\"1329\"\u003eEGFR tyrosine kinase inhibitor (TKI)\u003c\/strong\u003e, a subset of targeted anticancer agents. It belongs to the broader category of \u003cstrong data-start=\"1409\" data-end=\"1441\"\u003emolecular targeted therapies\u003c\/strong\u003e used in oncology.\u003c\/p\u003e\r\n\u003cp data-start=\"1461\" data-end=\"1546\"\u003e\u003cem data-start=\"1461\" data-end=\"1546\"\u003eReference: World Health Organization (WHO) guidelines on cancer treatment; U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1548\" data-end=\"1551\"\u003e\r\n\u003ch3 data-start=\"1553\" data-end=\"1599\"\u003eWhat is the mode of action of Gefitinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"1600\" data-end=\"2009\"\u003eGefitinib acts by selectively binding to the adenosine triphosphate (ATP) binding site of the EGFR tyrosine kinase domain. This inhibits the receptor’s autophosphorylation and downstream signaling through pathways such as MAPK, PI3K\/AKT, and STAT, which are critical for tumor growth and survival. Consequently, gefitinib impedes cancer cell proliferation and promotes apoptosis in tumors with EGFR mutations.\u003c\/p\u003e\r\n\u003cp data-start=\"2011\" data-end=\"2200\"\u003e\u003cem data-start=\"2011\" data-end=\"2200\"\u003eReference: PubMed (e.g., Lynch et al., 2004, “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib”); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2202\" data-end=\"2205\"\u003e\r\n\u003ch3 data-start=\"2207\" data-end=\"2252\"\u003eWhat are the primary uses of Gefitinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"2253\" data-end=\"2571\"\u003eGefitinib is primarily used for the treatment of advanced or metastatic non‑small cell lung cancer (NSCLC) in patients whose tumors have specific activating mutations in the EGFR gene. It is typically prescribed for patients who have either progressed on or are intolerant to standard chemotherapy or other treatments.\u003c\/p\u003e\r\n\u003cp data-start=\"2573\" data-end=\"2647\"\u003e\u003cem data-start=\"2573\" data-end=\"2647\"\u003eReference: U.S. FDA; ClinicalTrials.gov (e.g., NCT00121090, NCT00333590)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2649\" data-end=\"2652\"\u003e\r\n\u003ch3 data-start=\"2654\" data-end=\"2724\"\u003eWhat is the recommended dosage and administration for Gefitinib?\u003c\/h3\u003e\r\n\u003cul data-start=\"2725\" data-end=\"3051\"\u003e\r\n\u003cli data-start=\"2725\" data-end=\"2805\"\u003e\n\u003cstrong data-start=\"2727\" data-end=\"2738\"\u003eDosage:\u003c\/strong\u003e The standard oral dosage for gefitinib is \u003cstrong data-start=\"2781\" data-end=\"2802\"\u003e250 mg once daily\u003c\/strong\u003e.\u003c\/li\u003e\r\n\u003cli data-start=\"2806\" data-end=\"3051\"\u003e\n\u003cstrong data-start=\"2808\" data-end=\"2827\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2832\" data-end=\"3051\"\u003e\r\n\u003cli data-start=\"2832\" data-end=\"2960\"\u003eGefitinib is taken by mouth, with or without food, at approximately the same time each day to maintain steady plasma levels.\u003c\/li\u003e\r\n\u003cli data-start=\"2963\" data-end=\"3051\"\u003ePatients should follow dosing instructions as prescribed by their healthcare provider.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3053\" data-end=\"3128\"\u003e\u003cem data-start=\"3053\" data-end=\"3128\"\u003eReference: U.S. FDA Gefitinib Prescribing Information; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3130\" data-end=\"3133\"\u003e\r\n\u003ch3 data-start=\"3135\" data-end=\"3197\"\u003eWhat prescribing information is important for Gefitinib?\u003c\/h3\u003e\r\n\u003cul data-start=\"3198\" data-end=\"3917\"\u003e\r\n\u003cli data-start=\"3198\" data-end=\"3307\"\u003e\n\u003cstrong data-start=\"3200\" data-end=\"3216\"\u003eIndications:\u003c\/strong\u003e Gefitinib is indicated for patients with advanced NSCLC with sensitizing EGFR mutations.\u003c\/li\u003e\r\n\u003cli data-start=\"3308\" data-end=\"3522\"\u003e\n\u003cstrong data-start=\"3310\" data-end=\"3332\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3337\" data-end=\"3522\"\u003e\r\n\u003cli data-start=\"3337\" data-end=\"3441\"\u003eIt is contraindicated in patients with known hypersensitivity to gefitinib or any of its components.\u003c\/li\u003e\r\n\u003cli data-start=\"3444\" data-end=\"3522\"\u003eCaution is advised in patients with significant interstitial lung disease.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3523\" data-end=\"3720\"\u003e\n\u003cstrong data-start=\"3525\" data-end=\"3540\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3545\" data-end=\"3720\"\u003e\r\n\u003cli data-start=\"3545\" data-end=\"3720\"\u003eRegular evaluation of liver function tests, lung imaging (if respiratory symptoms occur), and monitoring for dermatologic and gastrointestinal adverse effects are essential.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3721\" data-end=\"3917\"\u003e\n\u003cstrong data-start=\"3723\" data-end=\"3750\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"3755\" data-end=\"3917\"\u003e\r\n\u003cli data-start=\"3755\" data-end=\"3822\"\u003eEGFR mutation testing is recommended before initiating therapy.\u003c\/li\u003e\r\n\u003cli data-start=\"3825\" data-end=\"3917\"\u003eUse in pregnant or breastfeeding women is not recommended due to potential teratogenicity.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3919\" data-end=\"4002\"\u003e\u003cem data-start=\"3919\" data-end=\"4002\"\u003eReference: U.S. FDA; National Comprehensive Cancer Network (NCCN) Guidelines; WHO\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4004\" data-end=\"4007\"\u003e\r\n\u003ch3 data-start=\"4009\" data-end=\"4107\"\u003eWhat safety information, side effects, warnings, and cautions are associated with Gefitinib?\u003c\/h3\u003e\r\n\u003cul data-start=\"4108\" data-end=\"5170\"\u003e\r\n\u003cli data-start=\"4108\" data-end=\"4243\"\u003e\n\u003cstrong data-start=\"4110\" data-end=\"4134\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4139\" data-end=\"4243\"\u003e\r\n\u003cli data-start=\"4139\" data-end=\"4195\"\u003eSkin rash, diarrhea, nausea, vomiting, and dry skin.\u003c\/li\u003e\r\n\u003cli data-start=\"4198\" data-end=\"4243\"\u003eMild elevations in liver enzymes may occur.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4244\" data-end=\"4503\"\u003e\n\u003cstrong data-start=\"4246\" data-end=\"4271\"\u003eSerious Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4276\" data-end=\"4503\"\u003e\r\n\u003cli data-start=\"4276\" data-end=\"4410\"\u003eInterstitial lung disease (ILD), which can be fatal; any new or worsening respiratory symptoms should prompt immediate evaluation.\u003c\/li\u003e\r\n\u003cli data-start=\"4413\" data-end=\"4503\"\u003eHepatotoxicity and rare cases of severe skin reactions such as Stevens-Johnson syndrome.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4504\" data-end=\"5057\"\u003e\n\u003cstrong data-start=\"4506\" data-end=\"4530\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4535\" data-end=\"5057\"\u003e\r\n\u003cli data-start=\"4535\" data-end=\"4669\"\u003e\n\u003cstrong data-start=\"4537\" data-end=\"4567\"\u003eInterstitial Lung Disease:\u003c\/strong\u003e Patients should be monitored for signs of ILD; treatment should be interrupted if ILD is suspected.\u003c\/li\u003e\r\n\u003cli data-start=\"4672\" data-end=\"4830\"\u003e\n\u003cstrong data-start=\"4674\" data-end=\"4693\"\u003eLiver Function:\u003c\/strong\u003e Periodic liver function tests are recommended; dose adjustment or discontinuation may be necessary if significant abnormalities occur.\u003c\/li\u003e\r\n\u003cli data-start=\"4833\" data-end=\"4918\"\u003e\n\u003cstrong data-start=\"4835\" data-end=\"4862\"\u003eDermatologic Reactions:\u003c\/strong\u003e Severe skin reactions require prompt medical attention.\u003c\/li\u003e\r\n\u003cli data-start=\"4921\" data-end=\"5057\"\u003e\n\u003cstrong data-start=\"4923\" data-end=\"4945\"\u003eDrug Interactions:\u003c\/strong\u003e Monitor for potential interactions with CYP3A4 inhibitors or inducers, which may alter gefitinib plasma levels.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5058\" data-end=\"5170\"\u003e\n\u003cstrong data-start=\"5060\" data-end=\"5074\"\u003ePregnancy:\u003c\/strong\u003e\r\n\u003cul data-start=\"5079\" data-end=\"5170\"\u003e\r\n\u003cli data-start=\"5079\" data-end=\"5170\"\u003eGefitinib is contraindicated in pregnant or breastfeeding women due to teratogenic risks.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5172\" data-end=\"5240\"\u003e\u003cem data-start=\"5172\" data-end=\"5240\"\u003eReference: U.S. FDA Gefitinib Prescribing Information; PubMed; WHO\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5242\" data-end=\"5245\"\u003e\r\n\u003ch3 data-start=\"5247\" data-end=\"5312\"\u003eWhat drug interactions should be considered with Gefitinib?\u003c\/h3\u003e\r\n\u003cul data-start=\"5313\" data-end=\"5700\"\u003e\r\n\u003cli data-start=\"5313\" data-end=\"5484\"\u003e\n\u003cstrong data-start=\"5315\" data-end=\"5337\"\u003eCYP3A4 Modulators:\u003c\/strong\u003e\r\n\u003cul data-start=\"5342\" data-end=\"5484\"\u003e\r\n\u003cli data-start=\"5342\" data-end=\"5484\"\u003eStrong CYP3A4 inhibitors (e.g., ketoconazole) can increase gefitinib levels, while inducers (e.g., rifampin) may decrease its effectiveness.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5485\" data-end=\"5700\"\u003e\n\u003cstrong data-start=\"5487\" data-end=\"5509\"\u003eOther Medications:\u003c\/strong\u003e\r\n\u003cul data-start=\"5514\" data-end=\"5700\"\u003e\r\n\u003cli data-start=\"5514\" data-end=\"5600\"\u003eConcomitant use of drugs that affect liver enzymes may alter gefitinib metabolism.\u003c\/li\u003e\r\n\u003cli data-start=\"5603\" data-end=\"5700\"\u003eUse caution with drugs that can exacerbate gastrointestinal toxicity or dermatologic reactions.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5702\" data-end=\"5764\"\u003e\u003cem data-start=\"5702\" data-end=\"5764\"\u003eReference: U.S. FDA; Clinical Pharmacology Reviews on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5766\" data-end=\"5769\"\u003e\r\n\u003ch3 data-start=\"5771\" data-end=\"5808\"\u003eFrequently Asked Questions (FAQs)\u003c\/h3\u003e\r\n\u003cp data-start=\"5810\" data-end=\"6038\"\u003e\u003cstrong data-start=\"5810\" data-end=\"5858\"\u003eQ: How quickly does Gefitinib start working?\u003c\/strong\u003e\u003cbr data-start=\"5858\" data-end=\"5861\"\u003eA: Some patients may begin to see improvements in symptoms within a few weeks, but maximum therapeutic effects are usually observed after several months of continuous treatment.\u003c\/p\u003e\r\n\u003cp data-start=\"6040\" data-end=\"6233\"\u003e\u003cstrong data-start=\"6040\" data-end=\"6080\"\u003eQ: Can Gefitinib be taken with food?\u003c\/strong\u003e\u003cbr data-start=\"6080\" data-end=\"6083\"\u003eA: Yes, gefitinib can be taken with or without food. However, it is important to take it at the same time each day to maintain consistent drug levels.\u003c\/p\u003e\r\n\u003cp data-start=\"6235\" data-end=\"6490\"\u003e\u003cstrong data-start=\"6235\" data-end=\"6337\"\u003eQ: What should I do if I experience a severe skin rash or breathing difficulty while on Gefitinib?\u003c\/strong\u003e\u003cbr data-start=\"6337\" data-end=\"6340\"\u003eA: Seek immediate medical attention, as these may be signs of serious adverse reactions such as Stevens-Johnson syndrome or interstitial lung disease.\u003c\/p\u003e\r\n\u003cp data-start=\"6492\" data-end=\"6693\"\u003e\u003cstrong data-start=\"6492\" data-end=\"6559\"\u003eQ: Is EGFR mutation testing required before starting Gefitinib?\u003c\/strong\u003e\u003cbr data-start=\"6559\" data-end=\"6562\"\u003eA: Yes, testing for EGFR mutations is typically recommended to ensure that patients with NSCLC will benefit from gefitinib therapy.\u003c\/p\u003e\r\n\u003cp data-start=\"6695\" data-end=\"6876\"\u003e\u003cstrong data-start=\"6695\" data-end=\"6737\"\u003eQ: How should missed doses be managed?\u003c\/strong\u003e\u003cbr data-start=\"6737\" data-end=\"6740\"\u003eA: If you miss a dose, take it as soon as you remember unless it is near the time of your next dose. Do not double the dose to catch up.\u003c\/p\u003e\r\n\u003cp data-start=\"6878\" data-end=\"6924\"\u003e\u003cem data-start=\"6878\" data-end=\"6924\"\u003eReference: U.S. FDA; NCCN Guidelines; PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"6926\" data-end=\"6929\"\u003e\r\n\u003ch3 data-start=\"6931\" data-end=\"7024\"\u003eWhere can I find additional clinical evidence and detailed information about Gefitinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"7025\" data-end=\"7118\"\u003eFor more in-depth clinical data, dosing guidelines, and safety monitoring, please refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"7119\" data-end=\"7556\"\u003e\r\n\u003cli data-start=\"7119\" data-end=\"7207\"\u003e\n\u003cstrong data-start=\"7121\" data-end=\"7173\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"7174\" data-end=\"7205\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"7208\" data-end=\"7297\"\u003e\n\u003cstrong data-start=\"7210\" data-end=\"7233\"\u003eClinicalTrials.gov:\u003c\/strong\u003e Search for gefitinib studies (e.g., NCT00121090, NCT00333540)\u003c\/li\u003e\r\n\u003cli data-start=\"7298\" data-end=\"7382\"\u003e\n\u003cstrong data-start=\"7300\" data-end=\"7311\"\u003ePubMed:\u003c\/strong\u003e For peer‑reviewed research articles on gefitinib and EGFR inhibitors\u003c\/li\u003e\r\n\u003cli data-start=\"7383\" data-end=\"7460\"\u003e\n\u003cstrong data-start=\"7385\" data-end=\"7421\"\u003eWorld Health Organization (WHO):\u003c\/strong\u003e Guidelines on lung cancer management\u003c\/li\u003e\r\n\u003cli data-start=\"7461\" data-end=\"7556\"\u003e\n\u003cstrong data-start=\"7463\" data-end=\"7523\"\u003eNational Comprehensive Cancer Network (NCCN) Guidelines:\u003c\/strong\u003e For treatment protocols in NSCLC\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7558\" data-end=\"7618\"\u003e\u003cem data-start=\"7558\" data-end=\"7618\"\u003eReference: U.S. FDA; ClinicalTrials.gov; PubMed; NCCN; WHO\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"7620\" data-end=\"7623\"\u003e\r\n\u003ch3 data-start=\"7625\" data-end=\"7645\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"7646\" data-end=\"8301\"\u003e\u003cstrong data-start=\"7646\" data-end=\"7659\"\u003eGefitinib\u003c\/strong\u003e (marketed as \u003cstrong data-start=\"7673\" data-end=\"7684\"\u003eIressa®\u003c\/strong\u003e and known by its research designation \u003cstrong data-start=\"7723\" data-end=\"7733\"\u003eZD1839\u003c\/strong\u003e) is a cornerstone targeted therapy for patients with advanced NSCLC harboring EGFR mutations. By inhibiting the EGFR tyrosine kinase, it effectively reduces tumor growth and improves clinical outcomes. However, careful patient selection (including EGFR mutation testing), monitoring for adverse effects (especially interstitial lung disease and hepatotoxicity), and managing potential drug interactions are essential for safe and effective therapy. Always consult with your healthcare provider to ensure that gefitinib is the appropriate treatment for your condition.\u003c\/p\u003e\r\n\u003cp data-start=\"8303\" data-end=\"8521\"\u003e\u003cem data-start=\"8303\" data-end=\"8521\"\u003eDisclaimer: This guide is intended for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e\r\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003c\/article\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"EZ Chemist","offers":[{"title":"250mg","offer_id":51735712071963,"sku":"IRESSA250mg","price":169.14,"currency_code":"USD","in_stock":true}],"url":"https:\/\/ezchemist.com\/products\/iressa","provider":"EZ Chemist","version":"1.0","type":"link"}